Logo image
Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
Journal article   Open access   Peer reviewed

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

Angela R Branche, Nadine G Rouphael, Cecilia Losada, Lindsey R Baden, Evan J Anderson, Anne F Luetkemeyer, David J Diemert, Patricia L Winokur, Rachel M Presti, Angelica C Kottkamp, …
Clinical infectious diseases, Vol.77(4), pp.560-564
08/15/2023
DOI: 10.1093/cid/ciad209
PMCID: PMC10443997
PMID: 37036397
url
https://doi.org/10.1093/cid/ciad209View
Published (Version of record) Open Access

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent SARS-CoV-2 mRNA vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wildtype spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.
Variant SARS-CoV-2 Vaccine

Details

Metrics

Logo image